INDUSTRIAL NEWS

Bioperfectus and HUIXIN Signed a Strategic Cooperation Agree

Release Time:2021/03/23 Click:

1.jpg2.jpg

On March 17th, Jiangsu Bioperfectus Technologies Co., Ltd. signed a strategic cooperation agreement with HUIXIN LABORATORY. Wang Guoqiang, General Manager of Bioperfectus Technologies, Liang Xiaobing, General Manager of HUIXIN LABORATORY, and senior executives of the two enterprises attended the signing ceremony.

 3.jpg

As the first molecular diagnostic company to be listed on the Science and Technology Innovation Board, Jiangsu Bioperfectus Technologies Co., Ltd. focuses on the two major areas of disease prevention and control (CDC) and clinical testing for women and children. After the outbreak of the novel crown epidemic, Bioperfectus Technologies took the lead in developing the novel crown nucleic acid detection reagents in the first time, and continued to provide strong reagents and instrument support for the prevention and control of the novel crown epidemic.

 

As a leading third-party medical testing center in the Greater Bay Area, HUIXIN LABORATORY is the first batch of novel coronavirus nucleic acid testing institutions approved by Zhuhai Municipal Government. Since the outbreak of the novel crown epidemic, HUIXIN LABORATORY has creatively set up 26 sampling points in multiple communities in Zhuhai. It has undertaken the work of novel coronavirus nucleic acid detection for more than 60% of the city's staff and all cold-chain food in the city, making a significant contribution to the prevention and control of the epidemic in Zhuhai.

 

About Jiangsu Bioperfectus Technologies Co., Ltd. 

BioPerfectus, a public listed company at Shanghai Stock Exchange (SSE:688399), is one of the leading molecular diagnostic solution manufacturers in global in-vitro diagnostics market since 2010. 

 

With headquarter located in Taizhou, branch offices sited in Shanghai, Xi’an and Beijing, Bioperfectus is pioneering in molecular diagnostics market with our products ranging from real time PCR kits, nucleic acid extraction systems, rapid tests and automation laboratory devices etc... 

 

Since the inception of International Sales and Marketing Division in June, 2020, under the authorization of international renowned public health organizations and institutions, our products have been distributing in over 50 countries all over the world and about to come to cover more countries in the near future. 

 

Young and passionate, Bioperfectus people are working steadily and firmly to achieve our dream to create a healthier future for our next generations.

Copyright © 2018 CACLP